The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 136,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in pharma: deuterated drug synthesis. Buy the report here.
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilizing and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
80+ innovations will shape the pharmaceutical industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 730,000 patents, there are 80+ innovation areas that will shape the future of the industry.
Within the emerging innovation stage, engineered multi-specific antibodies, tyrosine kinase inhibitors, and mutant DNA polymerases are disruptive technologies that are in the early stages of application and should be tracked closely. Peptide pharmacophores, antibody-drug conjugates, and neuroprotective drugs are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are amyloid precursor targeted therapies and modified vector HIV-1 vaccines, which are now well established in the industry.
Innovation S-curve for the pharmaceutical industry
Deuterated drug synthesis is a key innovation area in the pharmaceutical industry
Deuterated drug synthesis refers to the process of incorporating deuterium, an isotope of hydrogen, into drug molecules during the drug development process. Deuterium incorporation can lead to increased stability, improved pharmacokinetics, and reduced toxicity of the resulting drugs.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 440 companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of deuterated drug synthesis.
Key players in deuterated drug synthesis – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to deuterated drug synthesis
Company | Total patents (2021 - 2023) | Premium intelligence on the world's largest companies |
Immatics | 1755 | Unlock Company Profile |
Philip Morris International | 441 | Unlock Company Profile |
F. Hoffmann-La Roche | 432 | Unlock Company Profile |
Bristol-Myers Squibb | 408 | Unlock Company Profile |
Seagen | 349 | Unlock Company Profile |
OncoTherapy Science | 308 | Unlock Company Profile |
Bicycle Therapeutics | 297 | Unlock Company Profile |
Protagonist Therapeutics | 297 | Unlock Company Profile |
Takeda Pharmaceutical | 273 | Unlock Company Profile |
Centre National de la Recherche Scientifique | 234 | Unlock Company Profile |
Amgen | 219 | Unlock Company Profile |
Johnson & Johnson | 194 | Unlock Company Profile |
Royal Caribbean Cruises | 184 | Unlock Company Profile |
Apellis Pharmaceuticals | 180 | Unlock Company Profile |
Merck | 161 | Unlock Company Profile |
Caregen | 149 | Unlock Company Profile |
Ironwood Pharmaceuticals | 140 | Unlock Company Profile |
Ferring | 132 | Unlock Company Profile |
Aileron Therapeutics | 131 | Unlock Company Profile |
Ambrx Biopharma | 128 | Unlock Company Profile |
Baxter International | 120 | Unlock Company Profile |
GemVax & KAEL | 120 | Unlock Company Profile |
UCB | 115 | Unlock Company Profile |
Vertex Pharmaceuticals | 113 | Unlock Company Profile |
Palatin Technologies | 112 | Unlock Company Profile |
Ipsen | 107 | Unlock Company Profile |
Pfizer | 107 | Unlock Company Profile |
Forschungszentrum Julich | 97 | Unlock Company Profile |
Ministry of Trade and Industry, Singapore | 95 | Unlock Company Profile |
Shanghai Techwell Biopharmaceutical | 94 | Unlock Company Profile |
3-D Matrix | 94 | Unlock Company Profile |
Pierre Fabre Foundation | 89 | Unlock Company Profile |
Sanofi | 89 | Unlock Company Profile |
Agios Pharmaceuticals | 83 | Unlock Company Profile |
Apitope International | 83 | Unlock Company Profile |
Pharma Mar | 80 | Unlock Company Profile |
Novo Nordisk Foundation | 80 | Unlock Company Profile |
Novabiotics | 79 | Unlock Company Profile |
Equillium | 78 | Unlock Company Profile |
Zealand Pharma | 76 | Unlock Company Profile |
Astellas Pharma | 71 | Unlock Company Profile |
MorphoSys | 71 | Unlock Company Profile |
Zymeworks | 70 | Unlock Company Profile |
The Administrators of The Tulane Educational Fund | 69 | Unlock Company Profile |
AstraZeneca | 65 | Unlock Company Profile |
Heidelberg Pharma | 65 | Unlock Company Profile |
Ecole Polytechnique Federale de Lausanne | 64 | Unlock Company Profile |
Biocon | 62 | Unlock Company Profile |
Autoimmune Technologies | 61 | Unlock Company Profile |
Niox Group | 59 | Unlock Company Profile |
Source: GlobalData Patent Analytics
Bristol-Myers Squibb is one of the leading patent filers in deuterated drug synthesis. It has filed several patents for deuterium-based compounds and is currently working to develop and formulate these drugs.
In terms of application diversity, Hodogaya Chemical leads the pack, while Deuteria Beverages and E. Merck stood in the second and third positions, respectively.
By means of geographic reach, Kura Oncology held the top position, followed by Incyte and Lexicon Pharmaceuticals.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.